Article Data

  • Views 451
  • Dowloads 117

Original Research

Open Access

Disease-free ovarian cancer patients report severe pain and fatigue over time: prospective quality of life assessment in a consecutive series

  • S. Shinde1
  • T. Wanger2
  • P. Novotny3
  • M. Grudem1
  • A. Jatoi1,2,*,

1Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA

2Cancer Education Center, Mayo Clinic Cancer Center, Rochester, Minnesota, USA

3Department of Biostatistics, Mayo Clinic, Rochester, Minnesota, USA

DOI: 10.12892/ejgo2585.2015 Vol.36,Issue 2,April 2015 pp.150-154

Published: 10 April 2015

*Corresponding Author(s): A. Jatoi E-mail: jatoi.aminah@mayo.edu

Abstract

bjective: Among ovarian cancer patients, cancer treatment is aggressive and yet survival is often so limited; hence, this study sought to measure quality of life with the ultimate goal of identifying ways of improving it over the duration of these patients’ lives. Materials and Methods: The medical records of all ovarian cancer patients who received some/all of their initial chemotherapy at the Mayo Clinic in Rochester, Minnesota from late 2010 through 2012 were reviewed. Patient-reported quality of life was derived from the following ten-point linear analogue scale questions which had been administered to all patients: 1) How would you describe your degree of pain, on average? 2) How would you describe your level of fatigue, on average? 3) How would you describe your overall quality of life? Quality of life data were censored upon cancer recurrence. Results: Among 59 eligible patients, the median cumulative interval during which quality of life was serially assessed was 1.15 years (range: three months, 3.2 years). Area under the curve for pain, fatigue, and global quality of life showed no statistically significant differences between patients treated with dose-dense chemotherapy with carboplatin/paclitaxel (n=10) versus three-week chemotherapy with carboplatin/paclitaxel (n=36) versus other (n=13). Although pain, fatigue, and global quality of life improved over time, 35 of 59 (59%) patients reported grade 4 or worse pain during follow up, and 47 of 59 (80%) reported grade 4 or worse fatigue (higher scores denote worse pain or fatigue). After completion of cancer treatment, 30 (51%) described grade 4 or worse pain or fatigue. The most common pain site was the abdomen/pelvis, followed by the back, followed by the hands, feet, fingers, and toes. Conclusion: In ovarian cancer patients who remain cancer-free, severe pain and fatigue occur years after cancer treatment. Further research should focus on how best to address these symptoms.

Keywords

Pain; Fatigue; Quality of life; Ovarian cancer.

Cite and Share

S. Shinde,T. Wanger,P. Novotny,M. Grudem,A. Jatoi. Disease-free ovarian cancer patients report severe pain and fatigue over time: prospective quality of life assessment in a consecutive series. European Journal of Gynaecological Oncology. 2015. 36(2);150-154.

References

[1] Hess L.M., Stehman F.B.: “State of the science in ovarian cancer quality of life research: a systematic review”. Int. J. Gynecol. Cancer, 2012, 22, 1273.

[2] Greimel E., Kristensen G.B., van der Burg M.E., Coronado P., Rustin G., del Rio A.S., et al.: “Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neoadjuvant chemotherapy”. Gynecol. Oncol., 2013, 131, 437. doi: 10.1016/j.ygyno.2013.08.014. Epub 2013 Aug 27.

[3] Monk B.J., Huang H.Q., Burger R.A., Mannel R.S., Homesley H.D., Fowler J., et al.: “Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecological Oncology Group Study”. Gynecol. Oncol., 2013, 128, 573.

[4] Stark D., Nankivell M., Pujade-Lauraine E., Kristensen G., Elit L., Stockler M., et al.: “Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality of life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomized trial”. Lancet Oncol., 2013, 14, 236.

[5] Wenzel L.B., Huang H.Q., Armstrong D.K., Walker J.L., Cella D., Gynecologic Oncology Group: “Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecological Oncology Group Study”. J. Clin. Oncol., 2007, 25, 437.

[6] Katsumata N., Yasuda M., Isonishi S., Takahashi F., Michimae H., Kimura E., et al.: “Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3012): a randomized, controlled, open label trial”. Lancet Oncol., 2013, 14, 1020.

[7] Katsumata N., Yasuda M., Takahashi F., Isonishi S., Jobo T., Aoki D., et al.: “Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, openlabel, randomized controlled trial”. Lancet, 2009, 374, 1331.

[8] Kondapalli L.A., Dillon K.E., Sammel M.D., Ray A., Prewitt M., Ginsberg J.P., et al.: “Quality of life in female cancer survivors: is it related to ovarian reserve?” Qual. Life Res., 2013, 23, 585. doi: 10.1007/s11136-013-0473-y. Epub 2013 Jul 24.

[9] Clevenger L., Schrepf A., DeGeest K., Bender D., Goodheart M., Ahmed A., et al.: “Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis”. Cancer, 2013, 119, 3234.

[10] Gupta D., Braun D.P., Staren E.D., Markman M.: “Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer”. J. Ovarian Res., 2013, 6, 6.

[11] Angioli R., Plotti F., Aloisi A., Capriglione S., Terranova C., Ricciardi R., et al.: “Does extensive upper abdominal surgery during primary cytoreduction impact on long-term quality of life?” Int. J. Gynecol. Cancer, 2013, 23, 442.

[12] Penar-Zadarko B., Binkowska-Bury M., Wolan M., Gawelko J., Urbanski K.: “Longitudinal assessment of quality of life in ovarian cancer patients”. Eur. J. Oncol. Nurs., 2013, 17, 381.

[13] Pilger A., Richter R., Fotopoulou C., Beteta C., Klapp C., Sehouli J.: “Quality of life and sexuality of patients after treatment for gynaecological malignancies: results of a prospective study in 55 patients”. Anticancer Res., 2012, 32, 5045.

[14] Beesley V.L., Price M.A., Webb P.M., O’Rourke P., Marquart L., Australian Ovarian Cancer Study Group, et al.: “Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs”. Psychooncology, 2013, 22, 1565.

[15] Meraner V., Gamper E.M., Grahmann A., Giesinger J.M., Wiesbauer P., Sztankay M., et al.: “Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy”. BMC Cancer, 2012, 12, 12.

[16] Price M.A., Butow P.N., Costa D.S., King M.T., Aldridge L.J., Fardell J.E., et al.: “Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers”. Med. J. Aust., 2010, 193, S52.

[17] Zamurovic M., Mitrovic-Javanovic A., Jurisic A.: “Ovarian carcinoma patients — life quality analysis in the postoperative period — how to improve it?” Eur. J. Gynaecol. Oncol., 2010, 31, 672.

[18] Greimel E., Daghofer F., Petru E.: “Prospective assessment of quality of life in long-term ovarian cancer survivors”. Int. J. Cancer, 2011, 128, 3005.

[19] Kornblith A.B., Mirabeau-Beale K., Lee H., Goodman A.K., Penson R.T., Pereira L., et al.: “Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease”. J. Psychosoc. Oncol., 2010, 28, 451.

[20] Matulonis U.A., Kornblith A., Lee H., Bryan J., Gibson C., Wells C., et al.: “Long-term adjustment of early-stage ovarian cancer survivors”. Int. J. Gynecol. Cancer, 2008, 18, 1183.

[21] Javid S.H., Unger J.M., Gralow J.R., Moinpour C.M., Wozniak A.J., Goodwin J.W., et al.: “A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials”. Oncologist, 2012, 17, 1180.

[22] Gansler T., Jin M., Bauer J., Dahlquist K., Tis L., Sharpe K., et al.: “Outcomes of a cancer clinical trial matching service”. J. Cancer Edu., 2012, 27, 11.

[23] Butow P., Coates A., Dunn S., Bernhard J., Humy C.: “On the receiving end. IV: validation of quality of life indicators”. Ann. Oncol., 1991, 2, 597.

[24] Lavoie Smith E.M., Pang H., Cirrincione C., Fleishman S., Paskett E.D., Ahles T., et al.: “Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced peripheral painful peripheral neuropathy”. JAMA, 2013, 309, 1359.

[25] Matthews J.N., Altman D.G., Campbell M.J., Royston P.: “Analysis of serial measurements in medical research”. BMJ, 1990, 300, 230.

[26] Lorusso D., Mainenti S., Ferrandina G., Scambia G.: “Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials”. Expert Rev. Anticancer Ther., 2010, 10, 987.

[27] Birthi P., Sloan P.: “Interventional treatment of refractory cancer pain”. Cancer J., 2013, 19, 390.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top